Prevalence of Psoriatic Arthritis in Nagano Prefecture, Japan, and Efficacy of the Psoriasis Epidemiology Screening Tool: A Real-World Survey

被引:0
|
作者
Meling, Maureen Tania [1 ]
Ogawa, Eisaku [1 ]
Sato, Yuki [1 ]
Minagawa, Akane [1 ]
Kiniwa, Yukiko [1 ]
Okuyama, Ryuhei [1 ]
机构
[1] Shinshu Univ, Dept Dermatol, Sch Med, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan
关键词
fingernail alterations; joint symptoms; psoriasis; Psoriasis Epidemiology Screening Tool (PEST); psoriatic arthritis; CLINICAL CHARACTERISTICS; DERMATOLOGY; POPULATION;
D O I
10.1620/tjem.2022.J035
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pain, stiffness, and swelling are the main joint symptoms of psoriatic arthritis (PsA); however, they are also common symptoms of other joint diseases. Therefore, it is challenging to distinguish PsA from other joint diseases. To evaluate the prevalence of PsA and the frequency of joint symptoms in psoriasis patients, we conducted a prefecture-wide survey using the Psoriasis Epidemiology Screening Tool (PEST), a patient questionnaire for screening PsA to assess joint symptoms. Data were collected from 764 psoriasis patients, all of whom visited hospitals (55.1%) or clinics (44.9%) in Nagano Prefecture, Japan. The proportion of psoriasis patients with PsA was 6.5% (50 of 764); four patients (1.2%) with PsA were treated in clinics, while 46 patients (10.9%) were treated in hospitals. Based on the responses to the PEST, 18.1% of patients with psoriasis had joint symptoms. In contrast, 73.2% of psoriasis patients with joint symptoms did not have PsA. The PEST showed 52% sensitivity and 93.4% specificity for PsA. In addition, fingernail alterations were common in PsA. The proportion of the population with PsA was lower than reported previously in Japan. This may have been due to the enrollment of a large number of patients treated in clinics. Many patients with PsA were treated at hospitals, which likely reflects the tendency of patients with joint symptoms to receive intensive treatment in hospitals. In addition, based on the lower sensitivity of the PEST in this study, further studies are necessary to establish the validity of the PEST.
引用
收藏
页码:205 / 210
页数:6
相关论文
共 39 条
  • [21] Utilization of the Psoriasis Epidemiology Screening Tool (PEST): A Risk Stratification Strategy for Early Referral of Psoriatic Arthritis Patients to Minimize Irreversible Erosive Joint Damage
    Chang, Jasmine
    Litvinov, Ivan, V
    Ly, Christina
    Netchiporouk, Elena
    Tsoukas, Alexander
    Thuraisingam, Thusanth
    Starr, Michael
    Powell, Mathieu
    Christodoulou, George
    Shamout, Yassein
    JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2022, 26 (06) : 600 - 603
  • [22] Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study
    Kiltz, Uta
    Sfikakis, Petros P.
    Gaffney, Karl
    Sator, Paul-Gunther
    von Kiedrowski, Ralph
    Bounas, Andreas
    Gullick, Nicola
    Conrad, Curdin
    Rigopoulos, Dimitris
    Lespessailles, Eric
    Romanelli, Marco
    Ghislain, Pierre-Dominique
    Brandt-Juergens, Jan
    Rashkov, Rasho
    Aassi, Maher
    Orsenigo, Roberto
    Perella, Chiara
    Pournara, Effie
    Gathmann, Sven
    Jagiello, Piotr
    Veit, Justyna
    Augustin, Matthias
    ADVANCES IN THERAPY, 2020, 37 (06) : 2865 - 2883
  • [23] Real-World Experience with an Adalimumab Biosimilar (ABP 501) in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis in Europe: Results from the Adelphi Disease Specific Programme
    Jin, Ran
    Haughton, James M.
    Goddard, Emily J.
    Courmier, Delphine
    Radziszewski, Waldemar
    Meadows, Rachael H.
    Piercy, James
    Cohen, Stanley
    RHEUMATOLOGY AND THERAPY, 2025, : 469 - 492
  • [24] Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study
    Uta Kiltz
    Petros P. Sfikakis
    Karl Gaffney
    Paul-Gunther Sator
    Ralph von Kiedrowski
    Andreas Bounas
    Nicola Gullick
    Curdin Conrad
    Dimitris Rigopoulos
    Eric Lespessailles
    Marco Romanelli
    Pierre-Dominique Ghislain
    Jan Brandt-Jürgens
    Rasho Rashkov
    Maher Aassi
    Roberto Orsenigo
    Chiara Perella
    Effie Pournara
    Sven Gathmann
    Piotr Jagiello
    Justyna Veit
    Matthias Augustin
    Advances in Therapy, 2020, 37 : 2865 - 2883
  • [25] The safety assessment of ustekinumab on psoriasis and psoriatic arthritis: A real-world analysis based on the FDA adverse event reporting system database
    Zheng, Yu
    Gao, Xiao-Jing
    Huang, Ji-Jun
    Chen, Xiang-Ming
    Liao, Yue
    Liu, Jia-Min
    Zheng, Yan-Ling
    Zhao, Yu-Yang
    Ding, Rui-Lian
    Li, Xiao-Min
    Bu, Jin
    Shen, Er-Xia
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2025, 151
  • [26] Real-World Efficacy and Safety of Apremilast in Belgian Patients with Psoriatic Arthritis: Results from the Prospective Observational APOLO Study
    de Vlam, Kurt
    Toukap, Adrien Nzeusseu
    Kaiser, Marie-Joelle
    Vanhoof, Johan
    Remans, Philip
    Van den Berghe, Marthe
    Di Romana, Silvana
    Van den Bosch, Filip
    Lories, Rik
    ADVANCES IN THERAPY, 2022, 39 (02) : 1055 - 1067
  • [27] Real-World Efficacy and Safety of Apremilast in Belgian Patients with Psoriatic Arthritis: Results from the Prospective Observational APOLO Study
    Kurt de Vlam
    Adrien Nzeusseu Toukap
    Marie-Joëlle Kaiser
    Johan Vanhoof
    Philip Remans
    Marthe Van den Berghe
    Silvana Di Romana
    Filip Van den Bosch
    Rik Lories
    Advances in Therapy, 2022, 39 : 1055 - 1067
  • [28] Effect of Fatigue on Health-Related Quality of Life and Work Productivity in Psoriatic Arthritis: Findings From a Real-World Survey
    Gossec, Laure
    Walsh, Jessica A.
    Michaud, Kaleb
    Holdsworth, Elizabeth
    Peterson, Steve
    Meakin, Sophie
    Yang, Feifei
    Booth, Nicola
    Chakravarty, Soumya D.
    Piercy, James
    Dennis, Natalie
    Ogdie, Alexis
    JOURNAL OF RHEUMATOLOGY, 2022, 49 (11) : 1221 - 1228
  • [29] Real-world use of biological drugs in patients with psoriasis/psoriatic arthritis: a retrospective, population-based study of years 2010-2014 from Southern Italy
    Marciano, Ilaria
    Randazzo, Maria P.
    Panagia, Paolo
    Intelisano, Rosanna
    Sgroi, Carmela
    Ientile, Valentina
    Cannavo, Serafinella
    Guarneri, Claudio
    Reitano, Paolina
    Spina, Edoardo
    Trifiro, Gianluca
    GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, 2020, 155 (04): : 441 - 451
  • [30] Etanercept in Axial Spondyloarthritis, Psoriatic Arthritis, and Plaque Psoriasis: Real-World Outcome Data from German Non-interventional Study ADEQUATE
    Feist, Eugen
    Baraliakos, Xenofon
    Behrens, Frank
    Thaci, Diamant
    Plenske, Anja
    Klaus, Pascal
    Meng, Thomas
    RHEUMATOLOGY AND THERAPY, 2024, 11 (02) : 331 - 348